AbelZeta Earns EMA PRIME for C-CAR168 Lupus Therapy
ROCKVILLE, Md. & SHANGHAI, July 20, 2026 AbelZeta Pharma, Inc. has achieved a significant regulatory milestone after the European...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
ROCKVILLE, Md. & SHANGHAI, July 20, 2026 AbelZeta Pharma, Inc. has achieved a significant regulatory milestone after the European...
SAN ANTONIO, July 20, 2026 Valion Bio, Inc. has announced a significant clinical development milestone after Sheba Medical Center,...
MUMBAI, India & NAPLES, Fla., July 21, 2026 Lupin Limited has announced the strategic spin-out of two promising clinical-stage...
